Skip to main content

2 Result(s)

within Diane A. J. van der Biessen Remove this filter Biomedicine, general Remove this filter

and

  1. Article

    Open Access

    Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520

    BI 853520 is a potent inhibitor of focal adhesion kinase and is currently under clinical development for the treatment of non-hematological malignancies.

    Remy B. Verheijen, Diane A. J. van der Biessen, Sebastien J. Hotte… in Targeted Oncology (2019)

    Download PDF (623 KB) View Article

  2. Article

    Open Access

    Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

    Overexpression/activation of focal adhesion kinase (FAK) in human malignancies has led to its evaluation as a therapeutic target. We report the first-in-human phase I study of BI 853520, a novel, potent, highl...

    Maja J. A. de Jonge, Neeltje Steeghs, Martijn P. Lolkema… in Targeted Oncology (2019)

    Download PDF (702 KB) View Article